<p>CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO&#39;s recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.</p>

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Anchor (from Spotify)

BiotechTV - News

From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage